Everolimus-d4 – 1 mg

Brand:
Cayman
CAS:
1338452-54-2
Storage:
4
UN-No:
Non-Hazardous - /

Everolimus-d4 is intended for use as an internal standard for the quantification of everolimus (Item No. 11597) by GC- or LC-MS. Everolimus is a hydroxyethyl ether form of rapamycin (Item No. 13346) that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.{24850,24847} It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.{24847} Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.{24849,24846} It also acts as an immunosuppressive agent in the context of organ transplantation.  

 

Out of stock

SKU: 22559 - Category:

Description

An internal standard for the quantificaiton of everolimus by GC- or LC-MS,


Formal name: 42-O-(2-hydroxyethyl-1,1,2,2-d4)-rapamycin

Synonyms: 

Molecular weight: 962.3

CAS: 1338452-54-2

Purity: ≥99% deuterated forms (d1-d4); ≤1% d0

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|mTOR||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling||Research Area|Cancer|Metabolism||Research Area|Cell Biology|Cell Signaling|PI3K/Akt/mTOR Signaling